Combination treatment for advanced lung cancer after immunotherapy stops working
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two drugs (Adibelimab and Famitinib) plus chemotherapy for people with advanced non-small cell lung cancer whose previous immunotherapy (PD-1 inhibitor) has stopped working. The goal is to see if this new combination can help control the cancer when the first treatment fails.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with non-small cell lung cancer (NSCLC) that is stage IIIB or IV, and it has grown or spread despite previous treatment with a PD-1 inhibitor (a type of immunotherapy).
- You are in reasonably good general health (able to do daily activities).
- You are expected to live at least 3 more months.
- You have at least one tumor that can be measured and tracked by imaging.
- If you have brain metastases, they must be treated and stable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This study tests a new pill combined with immunotherapy for people with advanced non-small cell lung cancer that has not been treated or has stopped responding to previous immunotherapy. The goal is to see if the combination is safe and helps shrink tumors.
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
This trial tests a combination of two drugs, adebrelimab and irinotecan liposome, with or without a third drug called famitinib, for people with extensive-stage small cell lung cancer that has progressed after initial treatment with immunotherapy. The goal is to see if this combination can help control the cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.